Neuroleptic Malignant Syndrome
"Neuroleptic Malignant Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Descriptor ID |
D009459
|
| MeSH Number(s) |
C10.228.140.079.737 C10.720.737 C25.723.705.600
|
| Concept/Terms |
Neuroleptic Malignant Syndrome- Neuroleptic Malignant Syndrome
- Neuroleptic Malignant Syndromes
- Syndrome, Neuroleptic Malignant
- Syndromes, Neuroleptic Malignant
- NMS (Neuroleptic Malignant Syndrome)
- NMSs (Neuroleptic Malignant Syndrome)
Neuroleptic-Induced Neuroleptic Malignant Syndrome- Neuroleptic-Induced Neuroleptic Malignant Syndrome
- Neuroleptic Induced Neuroleptic Malignant Syndrome
- Neuroleptic-Malignant Syndrome, Neuroleptic Induced
- Neuroleptic Malignant Syndrome, Neuroleptic Induced
|
Below are MeSH descriptors whose meaning is more general than "Neuroleptic Malignant Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Neuroleptic Malignant Syndrome".
This graph shows the total number of publications written about "Neuroleptic Malignant Syndrome" by people in this website by year, and whether "Neuroleptic Malignant Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 5 | 0 | 5 |
| 2018 | 1 | 0 | 1 |
| 2020 | 5 | 0 | 5 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroleptic Malignant Syndrome" by people in Profiles.
-
Care of Parkinson's disease (PD) patients in times of covid-19 pandemic. Diabetes Metab Syndr. 2021 Jul-Aug; 15(4):102168.
-
Successful Emergency Treatment of Refractory Neuroleptic Malignant Syndrome With Electroconvulsive Therapy and a Novel Use of Dexmedetomidine: A Case Report From California in the Era of COVID-19. J ECT. 2021 03 01; 37(1):71-73.
-
Neuroleptic malignant syndrome following COVID-19 vaccination. Am J Emerg Med. 2021 11; 49:408-409.
-
The authors' response: Propofol in COVID 19: From basic science to clinical impact. Am J Emerg Med. 2021 07; 45:528.
-
A diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome. Am J Emerg Med. 2021 05; 43:272-273.
-
The authors' response: A diagnostic confusion between serotonin syndrome and neuroleptic malignant syndrome. Am J Emerg Med. 2021 05; 43:274.
-
Neuroleptic malignant syndrome in COVID-19 patients by Soh et al. Am J Emerg Med. 2021 05; 43:259.
-
Propofol and sedation in patients with coronavirus disease. Am J Emerg Med. 2021 Apr; 42:250.
-
Neuroleptic malignant syndrome in patients with COVID-19. Am J Emerg Med. 2020 10; 38(10):2243.e1-2243.e3.
-
Neuroleptic malignant syndrome in a COVID-19 patient. Brain Behav Immun. 2020 08; 88:28-29.